Our inflammation model recreates acute or chronic inflammatory states in human endothelial cells. This platform enables evaluation of compound efficacy and a reliable way to study inflammatory responses in a vascular micro-environment.
Acute persistent inflammation
› Non-alcoholic Steatohepatitis (NASH)
› Western Diet Obesity
› Atherosclerosis
› Diabetes-II
Chronic non-resolving inflammation
› Multiple Sclerosis
› Rheumatoid Arthritis
› Inflammatory Bowel Disease
Vascular pathologies
› Sickle Cell Disease
› Vascular Occlusion
› Ischemia
Anti-inflammatory drug development
› Therapeutic and prophylactic protocols available
› Multi-throughput screening
› Dose response analysis and IC50 determination
Mechanism of Action (MoA) studies
› Analysis of endothelial activation pathways
› Measurement of adhesion molecules and cytokines
› Identification of pro- or anti-inflammatory effects
Vascular modeling
› Regular vascular flow: leukocytes trafficking measurements (capture, rolling, migration and transmigration)
› Disruptive flow: monocytes or neutrophils platelet aggregates
› Rolling leukocyte flow: endothelial cells replaced by platelets
Chronic and acute disease modeling
› Acute-persistent inflammation:
• Neutrophil extra cellular traps (NETs)
• Oxidized low-density lipoprotein (OxLDL)
• Tumor necrosis factor superfamily (TNFSF14)
› Chronicnon-resolving inflammation:
• Tumor necrosis factor alpha (TNFα)
• Interfer on gamma (IFNɣ)
• Lipopolysaccharides (LPS)
Safety and toxicity assessment
› Endothelial cell activation and dysfunction
› Endothelial junctions integrity
Bio-imaging
› High-resolution imaging
by phase contrastmicroscopy
› Immunohistochemistry: visualisation of cellular morphology, drug-specific effect
› Adjustable time-course measurements
Cell tracking
› MesenCount and MesenTrack AI-based softwares
› Label-free or immunofluorescence imaging
under flow
Flow Cytometry
› Recovery and phenotyping of recruited leukocyte subsets in whole blood models
› Identification of endothelial cell activation markers
› Measurement of cytokines production
Example 1
Trafficking of human monocytes on activated HUVECs under flow
Trafficking of human monocytes on activated HUVECs under flow. Monocytes flowed over HUVECs for 5-mins (area marked in grey). They were tracked, andtheir positions marked at 1-min intervals. Monocytes captured from free-flow became rapidly activated by rolling on the luminal surface, changing phase from white(squares) to grey (triangles). Monocytes that underwent transmigration into the ablumen changed to phase-black (inverted triangles).
Example 2
Blockade in Monocyte transmigration identified with Compound-C
Success with a typical screening strategy
Monocyte transmigration on the surface of activated HUVECs under flow. Primary human monocytes co-cultured on TNFα-activated HUVECs. Test compounds at 30 µM or control were added to cells for 45 min and the transmigration blockade recorded.
MesenFlow Technologies SàrlAvenue de la Roseraie 64
1205, Geneva
Switzerland
+41 22 32 16 961 (office)
+41 79 36 66 291 (mobile)
